Skip to main content
JEIL PHARMACEUTICAL CO.,LTD logo

JEIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 271980 ISIN · KR7271980005 KO Manufacturing
Open in API
Filings indexed 135 across all filing types
Latest filing 2019-12-23 Major Shareholding Noti…
Country KR South Korea
Listing KO 271980

About JEIL PHARMACEUTICAL CO.,LTD

https://www.jeilpharm.co.kr/english/

JEIL PHARMACEUTICAL CO.,LTD. is a company engaged in the development, manufacturing, and distribution of pharmaceutical products. Its portfolio includes both finished drug products and Active Pharmaceutical Ingredients (APIs). The company produces a diverse range of dosage forms, such as solid medicines (tablets and capsules), patches, and injections, with a strategic focus on becoming a leading manufacturer of injection-based medicines. Committed to developing high-value products, the company operates KGMP-certified manufacturing facilities. Research and development activities are central to its operations, driven by its dedicated R&D center.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is the standard Korean regulatory filing for reporting significant changes in share ownership (often referred to as the '5% rule' filing). It details the reporting entity, the number of shares held, the purpose of holding, and specific transaction history (dates, methods, and amounts). This fits the definition of a Major Shareholding Notification (MRQ).
2019-12-23 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) filed by Jeil Pharmaceutical. It details specific transactions (purchases) made by major shareholders and executives, including the company's parent entity, Jeil Pharma Holdings, and individual directors. This type of filing is a standard regulatory requirement for disclosing changes in significant share ownership and insider holdings. In the provided taxonomy, 'Major Shareholding Notification' (MRQ) is the most accurate category for filings that report changes in significant share ownership levels and major shareholder status.
2019-12-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 98% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details changes in share ownership by a major shareholder (Jeil Pharma Holdings) in the issuing company (Jeil Pharmaceutical). This type of filing is a standard regulatory disclosure for insider/major shareholder transactions, which falls under the 'Major Shareholding Notification' category.
2019-12-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. It details share acquisitions by a major shareholder (Jeil Pharma Holdings) in Jeil Pharmaceutical. This type of filing is specifically categorized as 'Director's Dealing' (DIRS) in the provided schema, as it reports insider/major shareholder transactions.
2019-12-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and their special related parties, including specific transaction dates, methods (e.g., open market purchases), and collateral agreements. This falls under the category of Major Shareholding Notification.
2019-11-27 Korean
분기보고서 (2019.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Jeil Pharmaceutical Co., Ltd. covering the period from January 1, 2019, to September 30, 2019. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2019
2019-11-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.